Drug Evaluation in Angina Pectoris
Gianluigi Ardissino · Lionel H. Opie · Stefano Savonitto
2012 abe. · Developments in Cardiovascular Medicine 158. liburua · Springer Science & Business Media
Liburu elektronikoa
262
orri
reportBalorazioak eta iritziak ez daude egiaztatuta Lortu informazio gehiago
Liburu elektroniko honi buruz
Although there are many books on angina, few are devoted to the important problem of how to evaluate drug efficacy in angina pectoris. Drug Evaluation in Angina Pectoris has two fundamental aims: the first is to review the methodological aspects of drug evaluation in stable and unstable angina pectoris; the second is to provide a logical and methodological background for future studies aimed at assessing the ability of medical treatment to improve prognosis.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Part I updates the pathophysiology, clinical presentation and prognosis of angina pectoris. Part II aims to `put in numbers' the symptoms and signs of myocardial ischemia, starting from a revision of the currently used parameters. It is extremely important to quantify the variability of the disease for the correct design of clinical trial, a subject dealt with in Part III, which also discusses some clinico-pharmacological aspects of therapy. Part IV is a critical review of the drugs currently used for the treatment of stable and unstable angina, and particularly considers some important unresolved issues concerning their use. The current FDA and EC guidelines for the evaluation of antianginal drugs are briefly discussed in Part V, giving clinical investigators insight into how antianginal drugs are evaluated by regulatory agencies and what is considered as proof of a valid efficacy/tolerability ratio.
Drug Evaluation in Angina Pectoris will assist discerning cardiologists, pharmacologists, and advanced students of cardiology as well as innovative pharmaceutical companies, all of whom need to understand what angina is, how to evaluate treatment, and how to judge the agents used in its treatment.
Baloratu liburu elektroniko hau
Eman iezaguzu iritzia.
Irakurtzeko informazioa
Telefono adimendunak eta tabletak
Instalatu Android eta iPad/iPhone gailuetarako Google Play Liburuak aplikazioa. Zure kontuarekin automatikoki sinkronizatzen da, eta konexioarekin nahiz gabe irakurri ahal izango dituzu liburuak, edonon zaudela ere.
Ordenagailu eramangarriak eta mahaigainekoak
Google Play-n erositako audio-liburuak entzuteko aukera ematen du ordenagailuko web-arakatzailearen bidez.
Irakurgailu elektronikoak eta bestelako gailuak
Tinta elektronikoa duten gailuetan (adibidez, Kobo-ko irakurgailu elektronikoak) liburuak irakurtzeko, fitxategi bat deskargatu beharko duzu, eta hura gailura transferitu. Jarraitu laguntza-zentroko argibide xehatuei fitxategiak irakurgailu elektroniko bateragarrietara transferitzeko.
